| 2023 | A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients with Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone | 문영철 | Article |
| 2017 | A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalanprednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma | 문영철 | Article |
| 2014 | Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: A prospective multicenter study | 문영철 | Article |
| 2014 | Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: Web-based multicenter registry study | 문영철 | Article |
| 2012 | Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL) | 문영철 | Article |
| 2009 | Clinical features and survival outcomes in patients with multiple myeloma: Analysis of web-based data from the korean myeloma registry | 문영철 | Article |
| 2011 | Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: Surgical resection followed by chemotherapy versus chemotherapy alone | 문영철 | Article |
| 2021 | Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia | 문영철 | Article |
| 2021 | Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia | 문영철 | Article |
| 2011 | Immunoglobulin D multiple myeloma: Response to therapy, survival, and prognostic factors in 75 patients | 문영철 | Article |
| 2017 | Improved prognostic stratification using NCCN- and GELTAMOinternational prognostic index in patients with diffuse large B-cell lymphoma | 문영철 | Article |
| 2014 | Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea - Experience from 110 patients | 문영철 | Article |
| 2013 | Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT | 문영철 | Article |
| 2011 | Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL) | 문영철 | Article |
| 2018 | Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150) | 문영철 | Article |
| 2017 | Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia | 문영철 | Article |
| 2013 | Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib | 문영철 | Article |
| 2009 | Prognostic Factors and Clinical Outcomes of High-Dose Chemotherapy followed by Autologous Stem Cell Transplantation in Patients with Peripheral T Cell Lymphoma, Unspecified: Complete Remission at Transplantation and the Prognostic Index of Peripheral T Cell Lymphoma Are the Major Factors Predictive of Outcome | 문영철 | Article |
| 2015 | Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL) | 문영철 | Article |
